PRP in Aesthetic Medicine: What the Evidence Says

How claims are graded here

Every claim on this site sits in one of four groups, and the group matters more than the wording. Established means the claim follows from evidence that is consistent and is verifiable about the material itself — that it is prepared from the patient’s own blood at the point of care belongs here, and so does the absence of a cosmetic approval, which is a fact about the regulatory record rather than a finding about the material. Limited means there is real evidence but it is mixed or narrow. Hair loss is graded limited rather than established even though it is the strongest use in this group, because the studies disagree and the measures differ; facial skin is graded limited on smaller and weaker work. Emerging means the approach is plausible and early work points one way but the study that would settle it has not been done, which is where adding the material to another treatment sits. Not supported means the claim is made confidently and the evidence does not carry it. The reason for grading rather than simply reporting is that this material is discussed as though it were one thing. It is a preparation whose composition depends on the protocol used, so a study of one preparation is a study of that preparation, and a claim that the treatment works is a claim about a material that has not been defined.

Why there is no cosmetic approval

Platelet-rich plasma holds no approval as a cosmetic treatment, and the reason is structural rather than a gap that somebody forgot to fill. It is a biologic prepared at the point of care from the patient’s own blood and administered in the same session, so there is no manufactured product with a defined composition, a batch record and a release specification. Product authorisation attaches to products, and this is a process. The devices involved are regulated separately, as laboratory equipment, and their authorisation covers separating blood rather than producing a treatment. Two consequences follow. The first is that the claim made for the material has not been assessed by any regulator, because there is nothing to assess an authorisation against. The second is that the composition of what is injected depends on the kit, the device, the spin and the interval before use, and none of those is standardised between clinics. Rules for blood-derived treatments also differ between jurisdictions, and several regulators have issued guidance about how such treatments may be advertised, precisely because the absence of a product approval leaves the claims unregulated at the point where they are made. Where a service describes the treatment as approved, the useful follow-up is to ask what exactly was approved, because the preparation itself is not.

What the risks and limits actually are

The first risk belongs to the preparation rather than the substance. Because the material is made in the room from the person’s own blood, it is only as clean as the process that produced it, and blood handled outside a controlled laboratory is a medium in which bacteria grow readily. Infection introduced during preparation is the recognised risk of a point-of-care biologic, and it depends on the environment, the technique, the equipment and how long the material sits before it is used. The ordinary risks of an injection also apply: bruising, swelling, discomfort, and the possibility of a result the person does not like, which is more visible in the scalp than in most places because the treatment is often given across a wide area. The autologous nature of the material removes the risk of donor transmission and immune reaction and removes nothing else. There are limits that belong to the evidence and to the way this material is used. The preparation is not standardised, so studies describe particular protocols rather than the treatment in general, and results from one clinic’s method may not apply to another’s. The studies are small, they differ in what they measure, and few run long enough to show whether a change persists. A laboratory measurement of growth factor release is a real finding and cannot be compared directly with a clinical outcome. And because the material is reabsorbed, any effect that outlasts it requires a mechanism to explain it, which is where the reasoning is weakest.

What else is used, and what the honest comparison is

Doing nothing is an option and it belongs first, particularly where the concern is hair, because hair loss is often progressive and a treatment that has to be repeated indefinitely is a long commitment to an uncertain result. For hair loss specifically, established medical treatments exist that are taken or applied rather than injected, and they have their own evidence and their own limits. A comparison between those and an injected preparation is the one worth having, and it is not the comparison a brochure usually offers. Where the material is proposed as an addition to another treatment, the relevant question is whether the result would have been different without it, and that is a comparison almost nobody has made. Where facial volume or shape is the goal, a filler is the treatment designed for it, and a dissolvable gel filler has the further advantage of being correctable with an enzyme if the result is unwanted. Where skin quality is the goal, other options exist with their own evidence and this review does not rank them. There is also a reasonable position that is not indecision: a person may decide that a treatment whose concentration varies, whose evidence is mixed and which must be repeated indefinitely is not worth the commitment, and that is a decision rather than a gap in the plan. Which option applies is an individual clinical question, and this review does not answer it for anyone.

How this review is kept current

This subject moves on three clocks, and the fastest one is not the evidence. Supply moves quickly: kits, devices and protocols change, and a clinic’s method may differ from the method in any published study. Regulation moves more slowly and differently between countries, because the rules for blood-derived treatments are not uniform and a same-session autologous preparation is treated differently from a manufactured product in some jurisdictions and similarly in others. The evidence moves slowest, and it is unusually hard to move, because a study describes one protocol and the next clinic uses a different one. This review is therefore dated and revisited on a short cycle, and it covers three things. The first is whether any claim has moved between the four grading groups, in either direction, because a claim can become supported as well as cease to be. The second is regulatory status and any guidance on how such treatments may be described, since that is a checkable fact readers are entitled to have current. The third is whether the evidence base has changed in kind: another small series using another protocol is a different event from a comparison against an established alternative, and only the second can establish whether the treatment does something another option does not. Where this review is wrong, the correction is made to the page rather than noted elsewhere, and the date of the most recent review is shown on every page.

Related guides